News | October 21, 2014

Study Demonstrates Benefits of Corus CAD Gene Expression Test Use for African American Patients

Results indicate clinicians can use the test to rule out obstructive coronary artery disease in patients

October 21, 2014 — CardioDx Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, "The Use of a Gene Expression Score Showed Clinical Utility in Evaluating African Americans Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease in a Primary Care Practice," at the 36th annual North American Meeting of the Society for Medical Decision Making, taking place from Oct. 18-22 in Miami.

The study evaluated the clinical utility of the Corus CAD blood-based gene expression test in the assessment of 518 African American patients presenting with symptoms suggestive of obstructive coronary artery disease (CAD) in a primary care setting. The results demonstrate the impact of Corus CAD score on clinician decision-making: Patients with low Corus CAD scores ( ? 15) had a 95 percent decreased rate of referral for advanced cardiac testing compared to patients with elevated ( > 15) Corus CAD scores (8/214 vs. 227/304). By ruling out obstructive CAD early in the work-up, the Corus CAD test was able to help clinicians avoid unnecessary referrals to cardiology or advanced cardiac testing when their patients' symptoms are due to non-cardiac causes.

Corus CAD is a blood-based test incorporating age, sex, and gene expression measurements that provides a current-state assessment of obstructive CAD in non-diabetic patients presenting with non-acute typical or atypical symptoms. The results of the gene expression measurements are combined with the patient's age and sex in an algorithm that delivers a score representing the likelihood of obstructive CAD. With a 96 percent negative predictive value, Corus CAD can help clinicians accurately rule out obstructive CAD as the source of their patients' symptoms, so that they may investigate other non-cardiac causes.

"These results show that Corus CAD can be a powerful decision-making tool for clinicians guiding their African American patients through the diagnostic pathway for suspected obstructive CAD," says lead author Morris Brown, M.D., of Providence Medical Group in Dayton, Ohio. "Given the heterogeneity in clinical manifestations of suspected obstructive CAD amongst different ethnic populations in the United States, a convenient and accurate blood test like Corus CAD that is effective across a spectrum of patients provides tremendous clinical value, particularly when it allows us to avoid costly and potentially harmful cardiac tests for patients who don't need them."

Of the 518 patients enrolled in the study, 41 percent (n=214) had a low Corus CAD score, demonstrating that the test has high relevance to clinical practice for ruling out obstructive CAD in a significant number of patients in everyday practice. The authors concluded that Corus CAD improved care for those patients with a low score by avoiding unnecessary, and potentially invasive, advanced diagnostic testing.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init